Published in Medical Device Law Weekly, January 30th, 2005
Patients who respond to Phenoptin in the phase II clinical trial, as measured by a greater than 30% reduction in blood phenylalanine (Phe) levels following 8 days of treatment, will be eligible to enroll into the phase III trial expected to begin in the first quarter of 2005.
Margretta Seashore, MD, director of Genetic Consultation Service in the Department of Genetics at Yale University School of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Law Weekly